Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-361 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 0.000512 | uM | 10643.145 | 1.0250 | 1.1169 | 0.4356 | |
| MDA-MB-361 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 0.00256 | uM | 10643.145 | 1.0248 | 1.1157 | 0.4356 | |
| MDA-MB-361 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 0.0128 | uM | 10643.145 | 0.9999 | 0.9994 | 0.4356 | |
| MDA-MB-361 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 0.064 | uM | 10643.145 | 1.0368 | 1.1730 | 0.4356 | |
| MDA-MB-361 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 0.32 | uM | 10643.145 | 1.0755 | 1.3639 | 0.4356 | |
| MDA-MB-361 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 1.6 | uM | 10643.145 | 1.0302 | 1.1414 | 0.4356 | |
| MDA-MB-361 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 8 | uM | 10643.145 | 0.9553 | 0.8008 | 0.4356 | |
| MDA-MB-361 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 40 | uM | 10643.145 | 0.8326 | 0.3131 | 0.4356 | |
| MDA-MB-361 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 200 | uM | 10643.145 | 0.9295 | 0.6910 | 0.4356 | |
| MDA-MB-361 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 0.000512 | uM | 10999.145 | 1.0267 | 1.0703 | 0.7621 | |
| MDA-MB-361 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 0.00256 | uM | 10999.145 | 0.9555 | 0.8841 | 0.7621 | |
| MDA-MB-361 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 0.0128 | uM | 10999.145 | 0.9858 | 0.9627 | 0.7621 | |
| MDA-MB-361 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 0.064 | uM | 10999.145 | 1.0009 | 1.0023 | 0.7621 | |
| MDA-MB-361 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 0.32 | uM | 10999.145 | 0.9378 | 0.8384 | 0.7621 | |
| MDA-MB-361 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 1.6 | uM | 10999.145 | 0.9835 | 0.9567 | 0.7621 | |
| MDA-MB-361 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 8 | uM | 10999.145 | 0.9212 | 0.7958 | 0.7621 | |
| MDA-MB-361 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 40 | uM | 10999.145 | 0.9952 | 0.9874 | 0.7621 | |
| MDA-MB-361 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 200 | uM | 10999.145 | 0.9091 | 0.7649 | 0.7621 | |
| MDA-MB-361 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 0.000512 | uM | 12379.17 | 1.0242 | 1.0842 | 0.5805 | |
| MDA-MB-361 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 0.00256 | uM | 12379.17 | 1.0004 | 1.0014 | 0.5805 | |
| MDA-MB-361 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 0.0128 | uM | 12379.17 | 1.0618 | 1.2175 | 0.5805 | |
| MDA-MB-361 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 0.064 | uM | 12379.17 | 0.9836 | 0.9439 | 0.5805 | |
| MDA-MB-361 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 0.32 | uM | 12379.17 | 1.0426 | 1.1489 | 0.5805 | |
| MDA-MB-361 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 1.6 | uM | 12379.17 | 1.0364 | 1.1269 | 0.5805 | |
| MDA-MB-361 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 8 | uM | 12379.17 | 1.0238 | 1.0828 | 0.5805 |